

Anh T Le

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9202309/publications.pdf>

Version: 2024-02-01

12
papers

1,628
citations

1163117

8
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

2699
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013, 19, 1469-1472.	30.7	526
2	TRK1ng Down an Old Oncogene in a New Era of Targeted Therapy. <i>Cancer Discovery</i> , 2015, 5, 25-34.	9.4	509
3	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3334-3347.	7.0	182
4	The Incidence of Brain Metastases in Stage IV <i>ROS1</i> -Rearranged Non-small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1717-1726.	1.1	119
5	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 494-503.	2.5	85
6	An Activating <i>KIT</i> Mutation Induces Crizotinib Resistance in <i>ROS1</i> -Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1273-1281.	1.1	71
7	<i>EGFR</i> Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. <i>Cancer Research</i> , 2017, 77, 3551-3563.	0.9	65
8	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. <i>Clinical Cancer Research</i> , 2021, 27, 1463-1475.	7.0	52
9	The Democratization of the Oncogene. <i>Cancer Discovery</i> , 2014, 4, 870-872.	9.4	7
10	Oncogenic Fusions Involving Exon 19 of <i>ALK</i> . <i>Journal of Thoracic Oncology</i> , 2012, 7, e44.	1.1	6
11	Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to <i>RET</i> Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , 2021, 99, 435-447.	2.3	6
12	Incidence of <i>ERBB</i> gene fusions (<i>EGFR</i> , <i>ERBB2</i> , <i>ERBB4</i>) across tumor types. <i>Journal of Clinical Oncology</i> , 2021, 39, 3091-3091.	1.6	0